What up Bros Nation! How is it going?! I don’t know about you but this past week has felt kind of long with no midweek Money Talkz check in. How has the market been treating you? In my case I had my shares of ups and downs but for the week I’m up several hundred dollars across various investments. On the crypto side of things I’d say about the same. I’m up over seven hundred dollars through various crypto investments. Slow and steady progress while waiting for that one breakout. Anyway, welcome to another episode of Money Talk Sundayz. It’s your big bro Stevie Bee. Hit that like share and subscribe button on your way in the door. Let’s get to the news.

Vinco Ventures' (BBIG) stock price has remained very volatile in the last few days. On an overall basis, it has gained 160 percent in the last month or so. Since the beginning of 2021, BBIG stock is up by more than 480 percent.

Vinco Ventures is an acquisition company that focuses on the B.I.G. (buy, innovate, grow) strategy. It mainly works in the media and content space and tries to leverage the internal traffic platforms of Honey Badger and Social Pulse Media to determine the highest conversion traffic and target accordingly.

There have been many developments that have led to the wild ride for BBIG stock. First, BBIG and its joint venture partner Zash Global Media and Entertainment acquired a short-form video platform in July. Lomotif has more than 225 million app installations and over 31 million monthly active users worldwide. Since CCV's investment in 2018, the company has been among the fastest rising video-sharing social networking platforms, with 225+ million Lomotif app installations in over 200 international locations in 300+ languages. In accordance with outdoors monitoring providers, over 300 million movies are played on the platform monthly. Over 10 billion atomic UGC (User Generated Content) clips have been used to create greater than 750 million movies on the platform since its launch. In August, BBIG also launched a platform for music streaming and NFTs.

Another major catalyst for BBIG stock has been its rising popularity with social media sites, especially on Reddit and Stocktwits. The users are praying for a short squeeze and are buying the shares and call options with a potential short squeeze in mind.

The number of shares shorted is relatively small compared to the average trading volume of the stock. Therefore, the short squeeze catalyst might exhaust itself soon.

Recently, the company reported its second-quarter results, which were disappointing. Its operating loss for the second quarter was $4.97 million compared to $1.2 million in the second quarter of 2020. Its revenues for the second quarter of 2021 also declined by 48 percent YoY. Its financials haven't provided much strength to its fundamental investment case.

As far as valuation is concerned, BBIG stock is currently trading at a Last Twelve Months  Enterprise Value-to-revenue multiple of 34.8x. According to Yahoo Finance, the industry average is 1.65x. Therefore, BBIG is trading at a much higher premium than the industry. A lot of optimism has already been priced into the stock with nearly 500 percent gains YTD.

The stock closed Friday at 7.98 well above its 20-day moving average of 4.24. it had a trading volume of 126.6 million shares indicating a high interest and lots of activity/volatility in this stock. The shares traded lower with abnormally high volume most likely attributed to retail investors raking in profits. According to data from Benzinga Pro, Vinco Ventures has a total share float of 60.01 million, of which 11.67 million shares are sold short, representing 19.44% of shares sold short.

What up Bros Nation! How is it going?! I don’t know about you but this past week has felt kind of long with no midweek Money Talkz check in. How has the market been treating you? In my case I had my shares of ups and downs but for the week I’m up several hundred dollars across various investments. On the crypto side of things I’d say about the same. I’m up over seven hundred dollars through various crypto investments. Slow and steady progress while waiting for that one breakout. Anyway, welcome to another episode of Money Talk Sundayz. It’s your big bro Stevie Bee. Hit that like share and subscribe button on your way in the door. Let’s get to the news.

Call it the stock market’s version of the “sequel effect.” January’s meme stock runup was so enjoyable that investors can’t help but try short squeezes again. This week, the 15 most shorted stocks have risen 31%, wildly outperforming the S&P 500’s 0.76% gain over the same time. SPACs are just collateral damage of attention-deficit investors.

Vaxart, vaxart, vaxart. While doing my review of Vaxart for today’s episode I came across another biotech stock that’s competing with VXRT. That company is Oramed Pharmaceuticals. Oramed is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM.

Knowing there is another company working on a Covid pill how do they compare? Let’s start with the house favorite, VXRT.

Off rip, Vaxart has already obtained the FDA approval to begin phase 2 clinical trials with its tablet vaccine candidate. That trial will be commencing shortly. As of this recording VXRT is trading at 8.71. It closed Friday September 3rd 11 cents below it’s 20 day moving average with a trading volume of 2.89 million. The firm has a fifty day simple moving average of $8.17 and a 200-day simple moving average of $7.30. The company has a market capitalization of $1.10 billion.

Notably, Julie M. Cherrington joined VXRT Board of Directors. When Julie joined the board of Rakovina Therapeutics this is what they had to say about her.

"Julie M. Cherrington is an accomplished life science executive with a record of demonstrated success bringing drug candidates into human clinical trials and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products…”

She is a driving force for multiple products getting FDA approved and moved to market. She’s also served on the board of Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics to name a few.

Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.

Her credentials are not to be effed with at all. With that being said, Vaxart is in a good place to make some real game changing moves.

Oramed on the other hand has a few factors tipping the scale in their favor. Oramed (ORMP) has outperformed even Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX), the established vaccine makers that have already received FDA authorization for their messenger-RNA-based shots.

Welcome to Money Talk Sundayz everybody. I’m your investment bro Stevie Bee. First off I just want to say to the people of Louisiana and everyone effected by Hurricane Ida, stay strong, stay safe, and keep your head up. I lived through Hurricane Andrew so I know tough times are ahead especially with Covid in the mix. First responders, you are not valued nearly as much as you should be until something catastrophic occurs but just know, we appreciate everything you do. Again, everyone in the path of the storm, stay safe, stay resilient, and this too shall pass.

Bros Nation, again thanks for tuning in. Have some pertinent info to cover today that you should keep in mind going into this week. We’re going to talk VXRT. Can’t get enough VXRT as we anticipate the next moves. We’re also going to talk about BBIG (Vinco Ventures). I was just introduced to this stock this morning and from what I’ve seen so far I want in. So you know the deal. Hit that like share and subscribe buttons. Let your peeps know you’re here. Let’s get to it!

Subscribe: https://anchor.fm/moneytalksundayz/subscribe

Before I jump into Vaxart, I have to clear up some miscommunication from yesterday’s episode on MMAT. In that broadcast I stated I bought in on MMAT around 2.50. I was “guesstimating” where I bought in at because I was more focused on doing the broadcast. Several viewers have pointed out that MMAT has never gone down to 2.50. While that is not true because it has fallen that low if you look at the chart history but at the time I bought in it was not that low. I bought in at 2.86. not 2.50. That is the actual amount and not an estimate.

Now VXRT. So much like the rest of you, when I initially bought in on VXRT I knew nothing about a lawsuit. I had no clue that the SEC was investigating claims that Vaxart embellished its role in Operation Warp Speed. I’m sure to many of you listening right now this is news so first here’s a quick summary.

Last summer, in June to be precise, the company claimed it was one of the few companies selected to participate in Operation Warp Speed and that their oral vaccine was the only one being evaluated. That announcement reportedly caused prices to go up to $17 from less than $3 previously. Days after that occurrence, Armistice Capital LLC, the hedge company that partly controls Vaxart, sold a large number of shares raking in over $200 million in profit.

The thing is Vaxart was not among the companies selected by the Trump Organization to receive funding to support their research.

In October of last year, VXRT revealed in a filing with the SEC that they were under investigation by the Feds and SEC over that announcement. Additionally, the filing revealed that there were several similar lawsuits filed in California and one in Delaware since August alleging these violations by Vaxart and a number of its officers and directors.

Now technically, these types of lawsuits are common when a company makes outrageous claims to self promote and elevate their worth. It is commonly referred to as a pump and dump scheme. When the market catches up with the bogus claims share prices plummet and shareholders lose loads of cash thus prompting lawsuits.

Now Vaxart denied the claims stating, “The Vaxart non-human primate challenge study was organized and funded by Operation Warp Speed, as stated in the June 26, 2020 company press release. The statements made in that press release are accurate and any allegation to the contrary is baseless."

Fast forward to April of this year, hedge fund Armistice and crew filed a motion to dismiss the lawsuit. The motion hearing was set for May 13th at 10 AM.

Meta Materials (MMAT) is making moves bros nation. I was THIS close to missing the squeeze but thanks to one viewer by the name of Kathy I’m already on the train. The stock is up nearly 21% and rising. Back in May this stock was trading around the $3-4 range to surging up to a high of more than $21 in June. It has since pulled back but its rearing for another go. So what is MMAT? Is now a good time to jump in? Buy the rumor and sell the news! Let’s get to it.

Subscribe: https://anchor.fm/moneytalksundayz/subscribe

Welcome to Money Talkz. I’m your investment bro Stevie Bee and thanks for tuning in to another episode. Today we’re going to talk about Meta Materials. Make sure you hit that like button. Share with anyone you know that’s looking into MMAT. Subscribe to the podcast or the youtube channel so you can always be up on the latest. Again thank you to all the viewers, all the listeners. Your engagement and interaction is doing so much more than you realize so THANK YOU!

Meta Materials, ticket symbol MMAT, engages in the manufacture and development of functional materials servicing various sectors and industries. Its technology platform enables the global brands to deliver products to customers in consumer electronics, 5G communications, health and wellness, aerospace, automotive, and clean energy. With such a diverse output its no wonder the benefits of meta is finally coming to light.

Meta was founded by George Palikaras and Themos Kallos on the 15th of August 2011. It is based in Nova Scotia, Canada. The company delivers previously unachievable performance across a range of applications by inventing designing, developing, and manufacturing sustainable, highly functional materials. This producer of high-performance nanocomposites and functional materials has seen a boon as a result of a variety of factors.

Factor 1: MMAT has formed a scientific advisory board. This group of award-winning scientists will be a catalyst the company hopes will drive future innovation. Indeed, as a company that is on the cutting edge of technological breakthroughs in the high-tech materials it produces, investors appear to be betting on a stronger and more diverse pipeline of prospective products in the future.

Additionally, one of the goals for this board to to assess new opportunities for mergers and acquisitions (M&A). Meta Materials has grown in a number of ways, and one has been through acquiring strategic technologies. The hope is that this group of experts can guide such decisions in a way that’s positive for shareholders.

The announcement of this board has investors looking past the hype of the stock and considering that actual soundness of the company. Investors can now focus on the science of MMAT and speculate about their innovative prowess. The more products Meta Materials can put in its pipeline, the greater the likelihood of explosive long-term growth.

Factor 2: Growth stocks in general are getting a lifeline from the Federal Reserve. Investors are factoring in the continuation of easy money policies, providing a more generalized boost to growth stocks.

Factor 3: Most importantly, MMAT is in the crosshairs of retail traders as a short-squeeze candidate. It has a relatively small float. The previous squeeze last quarter saw the share price go up nearly twenty dollars. Now trading around $4.15 per share, investors who are looking to take a flyer on a potential near-term winner appear to be piling into this speculative play.

As I mentioned before, I am invested in it. I don’t have nearly as many shares as I do VXRT or BTX but I have a good enough number starting off. Thanks again to Kathy for requesting a review of this stock.

Meta Materials (MMAT) is making moves bros nation. I was THIS close to missing the squeeze but thanks to one viewer by the name of Kathy I’m already on the train. The stock is up nearly 21% and rising. Back in May this stock was trading around the $3-4 range to surging up to a high of more than $21 in June. It has since pulled back but its rearing for another go. So what is MMAT? Is now a good time to jump in? Buy the rumor and sell the news! Let’s get to it.

Subscribe: https://anchor.fm/moneytalksundayz/subscribe

Welcome to Money Talkz. I’m your investment bro Stevie Bee and thanks for tuning in to another episode. Today we’re going to talk about Meta Materials. Make sure you hit that like button. Share with anyone you know that’s looking into MMAT. Subscribe to the podcast or the youtube channel so you can always be up on the latest. Again thank you to all the viewers, all the listeners. Your engagement and interaction is doing so much more than you realize so THANK YOU!

Meta Materials, ticket symbol MMAT, engages in the manufacture and development of functional materials servicing various sectors and industries. Its technology platform enables the global brands to deliver products to customers in consumer electronics, 5G communications, health and wellness, aerospace, automotive, and clean energy. With such a diverse output its no wonder the benefits of meta is finally coming to light.

Meta was founded by George Palikaras and Themos Kallos on the 15th of August 2011. It is based in Nova Scotia, Canada. The company delivers previously unachievable performance across a range of applications by inventing designing, developing, and manufacturing sustainable, highly functional materials. This producer of high-performance nanocomposites and functional materials has seen a boon as a result of a variety of factors.

Factor 1: MMAT has formed a scientific advisory board. This group of award-winning scientists will be a catalyst the company hopes will drive future innovation. Indeed, as a company that is on the cutting edge of technological breakthroughs in the high-tech materials it produces, investors appear to be betting on a stronger and more diverse pipeline of prospective products in the future.

Additionally, one of the goals for this board to to assess new opportunities for mergers and acquisitions (M&A). Meta Materials has grown in a number of ways, and one has been through acquiring strategic technologies. The hope is that this group of experts can guide such decisions in a way that’s positive for shareholders.

The announcement of this board has investors looking past the hype of the stock and considering that actual soundness of the company. Investors can now focus on the science of MMAT and speculate about their innovative prowess. The more products Meta Materials can put in its pipeline, the greater the likelihood of explosive long-term growth.

Factor 2: Growth stocks in general are getting a lifeline from the Federal Reserve. Investors are factoring in the continuation of easy money policies, providing a more generalized boost to growth stocks.

Factor 3: Most importantly, MMAT is in the crosshairs of retail traders as a short-squeeze candidate. It has a relatively small float. The previous squeeze last quarter saw the share price go up nearly twenty dollars. Now trading around $4.15 per share, investors who are looking to take a flyer on a potential near-term winner appear to be piling into this speculative play.

As I mentioned before, I am invested in it. I don’t have nearly as many shares as I do VXRT or BTX but I have a good enough number starting off. Thanks again to Kathy for requesting a review of this stock.

Brooklyn ImmunoTherapeutics Inc (BTX) is a clinical stage biopharmaceutical company. BTX stock is higher by 28.44% over the past week up 4.69% while the S&P 500 is down -0.09% as of 10:09 AM on Thursday, Aug 26. BTX had its gamestopping moment in April, rising nearly 20x. Within a month after the company arrived in the stock market, the stock went up 1800%, and this fetal stage company suddenly had a market cap of nearly $2bn… but can it make a Gamestop type comeback? Let’s find out.

Subscribe: https://anchor.fm/moneytalksundayz/subscribe

Welcome to Money Talkz, my midweek broadcast for Money Talk Sundayz. It’s your investment bro Stevie Bee. You know the rules… shoot me a like, share, and subscribe if you haven’t done so already. I want to give you guys a special shout out for making the podcast numbers double this week. I was looking at the metrics and was pleasantly surprised so thank you very much. Let’s keep that same energy going. As always if you have a request, please drop it in the comments or send me a message and I will definitely get to it asap. Finally hit that support link in the description box and we can keep it moving.

If you haven’t figured it out already I have a thing for biotech/biopharma stocks. I[ve said it previously. I work in IT supporting the healthcare field so I have almost an insider view to certain takeaways when it comes to these stocks. Today, I want to talk BTX, or Brooklyn ImmunoTherapeutics Inc. Earlier this year I jumped in on this stock and made $300 in the first 30 minutes and bounced. It pulled back and then went for a bigger run (which I jumped in on as well) before collapsing under the weight of the short squeeze. Since then, I’ve been monitoring and occasionally buying up more shares in anticipation of another rally. But the question is:

Is there another rally in store in the near future for BTX?

Let’s look at how BTX got started.

That first short squeeze started off with a Bloomberg article on April 6, and it happened for a number of reasons:

BTX had a super ultra float, just about 1.12 million shares in March when it launched.

Its precursor company, NTN Buzztime, had a high short interest, and although there was absolutely no relation between the two businesses, the short interest carried through.

r/wallstreetbets and other retail social media hotspots were abuzz with an interest in squeezing the biopharma sector.

On April 5, 2 million shares of BTX were traded. On April 6, that number jumped to 44 million! All these things coalesced together to give BTX that tremendous boost. That rocket launch had absolutely nothing to do with the company's development profile or fundamentals. The fundamentals have been referred to as terrible at best. The company was very low on cash when they launched, and - based on just the science, the management, or the fundamentals - nobody seemed too interested in Brooklyn Therapeutics.

Out of nowhere, and with the help of publicity from the Bloomberg article people started taking notice including retail investors frequenting wallstreetbets’ reddit platform. The smart thing that the company did was to take advantage of the squeeze to issue and sell additional shares of its own. Within 2 weeks of the start of the squeeze, they entered into an agreement with Lincoln Park to sell $20 million worth of freshly issued shares to them. A month later, they amended the agreement to sell $40 million worth of shares. This raised the cash reserves of the company considerably, while adding to the shares outstanding, and eventually to the float. Currently, shares outstanding are 42 million, and the float is 28 million.

The biggest development for the company has been the $125mn deal to acquire Novellus Therapeutics. The deal consists of $17.4M in cash and $107.6M in Brooklyn shares.

Brooklyn ImmunoTherapeutics Inc (BTX) is a clinical stage biopharmaceutical company. BTX stock is higher by 28.44% over the past week up 4.69% while the S&P 500 is down -0.09% as of 10:09 AM on Thursday, Aug 26. BTX had its gamestopping moment in April, rising nearly 20x. Within a month after the company arrived in the stock market, the stock went up 1800%, and this fetal stage company suddenly had a market cap of nearly $2bn… but can it make a Gamestop type comeback? Let’s find out.

Subscribe: https://anchor.fm/moneytalksundayz/subscribe

Welcome to Money Talkz, my midweek broadcast for Money Talk Sundayz. It’s your investment bro Stevie Bee. You know the rules… shoot me a like, share, and subscribe if you haven’t done so already. I want to give you guys a special shout out for making the podcast numbers double this week. I was looking at the metrics and was pleasantly surprised so thank you very much. Let’s keep that same energy going. As always if you have a request, please drop it in the comments or send me a message and I will definitely get to it asap. Finally hit that support link in the description box and we can keep it moving.

If you haven’t figured it out already I have a thing for biotech/biopharma stocks. I[ve said it previously. I work in IT supporting the healthcare field so I have almost an insider view to certain takeaways when it comes to these stocks. Today, I want to talk BTX, or Brooklyn ImmunoTherapeutics Inc. Earlier this year I jumped in on this stock and made $300 in the first 30 minutes and bounced. It pulled back and then went for a bigger run (which I jumped in on as well) before collapsing under the weight of the short squeeze. Since then, I’ve been monitoring and occasionally buying up more shares in anticipation of another rally. But the question is:

Is there another rally in store in the near future for BTX?

Let’s look at how BTX got started.

That first short squeeze started off with a Bloomberg article on April 6, and it happened for a number of reasons:

BTX had a super ultra float, just about 1.12 million shares in March when it launched.

Its precursor company, NTN Buzztime, had a high short interest, and although there was absolutely no relation between the two businesses, the short interest carried through.

r/wallstreetbets and other retail social media hotspots were abuzz with an interest in squeezing the biopharma sector.

On April 5, 2 million shares of BTX were traded. On April 6, that number jumped to 44 million! All these things coalesced together to give BTX that tremendous boost. That rocket launch had absolutely nothing to do with the company's development profile or fundamentals. The fundamentals have been referred to as terrible at best. The company was very low on cash when they launched, and - based on just the science, the management, or the fundamentals - nobody seemed too interested in Brooklyn Therapeutics.

Out of nowhere, and with the help of publicity from the Bloomberg article people started taking notice including retail investors frequenting wallstreetbets’ reddit platform. The smart thing that the company did was to take advantage of the squeeze to issue and sell additional shares of its own. Within 2 weeks of the start of the squeeze, they entered into an agreement with Lincoln Park to sell $20 million worth of freshly issued shares to them. A month later, they amended the agreement to sell $40 million worth of shares. This raised the cash reserves of the company considerably, while adding to the shares outstanding, and eventually to the float. Currently, shares outstanding are 42 million, and the float is 28 million.

The biggest development for the company has been the $125mn deal to acquire Novellus Therapeutics. The deal consists of $17.4M in cash and $107.6M in Brooklyn shares.

What up Bros Nation. How’s it going, how’s it going? Hope you’re having a good weekend and ready to get back to this money. It’s our first official Money Talk Sundayz livestream. Let’s see how this goes. On the agenda today: my latest update on Vaxart (VXRT). Anyway, you know the drill. Hit that like share and subscribe and don’t forget to hit that support link in the description box. Get your whiteboard or notebook ready. Let’s get to it. Drop the beat!

Support: https://anchor.fm/moneytalksundayz/support

Welcome again to Money Talk Sundays. Let’s talk VXRT. On Thursday the company announced the creation of an eight-member Scientific and Clinical Advisory Board. Interestingly enough, even though it was just recently announced, the board's first meeting occurred on July 24, 2021 and is comprised of medical and health care professionals who are vaccine, research, and academic experts in immunology, microbiology, and infectious diseases.

"We are excited to have such preeminent leaders in their fields joining our Scientific and Clinical Advisory Board," said Vaxart's Chief Executive Officer. "We believe their participation reflects the seriousness of our mission, our science, and the disruptive promise of our oral vaccines. We will benefit from access to their years of experience and deep expertise as we continue to advance our portfolio of programs."

"I am excited by the work Vaxart is doing and the promise its work holds for improving public health," said Advisory Board member Dr. Robert B. Belshe, Adorjan Endowed Professor Emeritus of Infectious Diseases and Immunology at Saint Louis University.

"A room-temperature stable pill has the promise to change how we vaccinate people both in the U.S. and abroad. An oral tablet vaccine could help vaccinate more people sooner in more corners of the world, and thus has the potential to make a major contribution to public health globally," Dr. Belshe added.

The eight leaders joining Vaxart's Scientific and Clinical Advisory Board are:   

Ralph Baric, Ph.D.   

Professor, Department of Epidemiology, Microbiology, and Immunology   

Gillings School of Global Public Health   University of North Carolina

Robert Belshe, M.D.   

Professor Emeritus, Division of Infectious Diseases, Allergy, and Immunology,   

Founder, Center for Vaccine Development   

St. Louis University

Stefan Gravenstein, M.D.   

Professor of Medicine,   

Director, Division of Geriatrics and Palliative Care   

Brown University

Gregory Gray, M.D.   

Professor of Medicine, Division of Infectious Diseases   

Duke University School of Medicine

Harry Greenberg, M.D.  

Joseph D. Grant Professor in the School of Medicine,  

Associate Dean for Research  

Stanford University

Marion Pepper, Ph.D.   

Associate Professor, Immunology   

University of Washington

Stanley A. Plotkin, M.D.   

Emeritus Professor, University of Pennsylvania   

Adjunct Professor, Johns Hopkins University   

Principal, Vaxconsult, LLC

George Siber, M.D.   

Member, Board of Directors, Affinivax    

Adjunct Professor, Johns Hopkins School of Medicine

Now word is making its rounds that VXRT isn’t going to be playing the waiting game and wait for Uncle Sam. My prediction for VXRT hasn’t changed. If you haven’t started investing do so now. It is currently trading at 8.34. Let’s see how it does in premarket trading in the am.

What up Bros Nation. How’s it going, how’s it going? Hope you’re having a good weekend and ready to get back to this money. It’s our first official Money Talk Sundayz livestream. Let’s see how this goes. On the agenda today: my latest update on Vaxart (VXRT). Anyway, you know the drill. Hit that like share and subscribe and don’t forget to hit that support link in the description box. Get your whiteboard or notebook ready. Let’s get to it. Drop the beat!

Support: https://anchor.fm/moneytalksundayz/support

Welcome again to Money Talk Sundays. Let’s talk VXRT. On Thursday the company announced the creation of an eight-member Scientific and Clinical Advisory Board. Interestingly enough, even though it was just recently announced, the board's first meeting occurred on July 24, 2021 and is comprised of medical and health care professionals who are vaccine, research, and academic experts in immunology, microbiology, and infectious diseases.

"We are excited to have such preeminent leaders in their fields joining our Scientific and Clinical Advisory Board," said Vaxart's Chief Executive Officer. "We believe their participation reflects the seriousness of our mission, our science, and the disruptive promise of our oral vaccines. We will benefit from access to their years of experience and deep expertise as we continue to advance our portfolio of programs."

"I am excited by the work Vaxart is doing and the promise its work holds for improving public health," said Advisory Board member Dr. Robert B. Belshe, Adorjan Endowed Professor Emeritus of Infectious Diseases and Immunology at Saint Louis University.

"A room-temperature stable pill has the promise to change how we vaccinate people both in the U.S. and abroad. An oral tablet vaccine could help vaccinate more people sooner in more corners of the world, and thus has the potential to make a major contribution to public health globally," Dr. Belshe added.

The eight leaders joining Vaxart's Scientific and Clinical Advisory Board are:   

Ralph Baric, Ph.D.   

Professor, Department of Epidemiology, Microbiology, and Immunology   

Gillings School of Global Public Health   University of North Carolina

Robert Belshe, M.D.   

Professor Emeritus, Division of Infectious Diseases, Allergy, and Immunology,   

Founder, Center for Vaccine Development   

St. Louis University

Stefan Gravenstein, M.D.   

Professor of Medicine,   

Director, Division of Geriatrics and Palliative Care   

Brown University

Gregory Gray, M.D.   

Professor of Medicine, Division of Infectious Diseases   

Duke University School of Medicine

Harry Greenberg, M.D.  

Joseph D. Grant Professor in the School of Medicine,  

Associate Dean for Research  

Stanford University

Marion Pepper, Ph.D.   

Associate Professor, Immunology   

University of Washington

Stanley A. Plotkin, M.D.   

Emeritus Professor, University of Pennsylvania   

Adjunct Professor, Johns Hopkins University   

Principal, Vaxconsult, LLC

George Siber, M.D.   

Member, Board of Directors, Affinivax    

Adjunct Professor, Johns Hopkins School of Medicine

Now word is making its rounds that VXRT isn’t going to be playing the waiting game and wait for Uncle Sam. My prediction for VXRT hasn’t changed. If you haven’t started investing do so now. It is currently trading at 8.34. Let’s see how it does in premarket trading in the am.

What’s going on Bros Nation. I’m back again with another episode of Money Talkz. Today’s episode is by viewer request. We’re going to talk Atossa Therapeutics. Before we get into it you know the drill, show some love with that like share and subscribe. Click the link in the description box to support the channel. Let’s grow this channel and this community of marathoners and let’s get to it.

Support: https://anchor.fm/moneytalksundayz/support

Atossa Therapeutics, ticket symbol ATOS. I have shares of this stock. I started investing in this stock back on the first of June when it was 3.64. It is currently at 3.225 so I’m down just a tad…. But what is the outlook for this stock? What’s going on in the world with this stock? Who is Atossa Therapeutics?

Let’s tackle the who first. ATOS is a clinical-stage biotech company whose surge in 2021 soon proved to be unsustainable. It underwent a meteoric rise from $1.52 in April to a 52-week high of $9.80 in June. But now it’s back down to the $3.20 area.

According to Yahoo! Finance “Atossa Therapeutic … discovers and develops medicines in the areas of oncology and infectious diseases. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer.”

This all sounds good and all but what is going on with the company? Good intentions aside is this a stock worth investing in?

Well, let’s take a look at a few factors.

ATOS is down 20% in a month. The company announced its Q2 2021 financial results and offered corporate updates on recent development.

In Q2, the company received final findings from the open-label Phase II clinical study of oral Endoxifen during the “window of opportunity” between breast cancer diagnosis and surgery. Endoxifen achieved the primary endpoint in the study with a 65.1% reduction of Ki-67, which is a common tumor cell activity measure. Also, Swedish regulators gave the company authorization to commence Phase 2 clinical trial of Endoxifen in mammographic breast density reduction.

In addition, Australian regulators approved the commencement of the AT-H201 clinical study being developed for COVID-19 treatment. Atossa released final data from the Phase 1 randomized, double-blinded, sham-controlled study using its novel drug candidate AT-301, developed as a nasal spray for home use for patients diagnosed with COVID-19. The company is witnessing progress in its COVID-19 and MD programs. So, with the progress, ATOS is worth watching in the coming months.

Also, the company joined the Russell 2000 and Russell 3000 Indexes fueling June’s price jump. Institutional investors and index funds had to buy the stock due to its inclusion in these major stock indexes.

But!

ATOS has had ZERO revenue. Nada. Zilch. So to continue operations ATOS is going to need to raise some cash. The most plausible option at this point would be for the company to issue more shares leading to stock dilution. And that just might be the case with the upcoming special meeting. This meeting is going to address the cash flow problem by voting on whether the total number of common shares of stock will be raised by 100 million. It would help fund the company’s growth but at the same time a stock dilution will hurt current investors. The company’s current cash flow stands at a $12.75 million loss. What is problematic about the stock is that the company is burning cash like a fire sale. In 2019 the free cash flow was -9.14 million. In 2020 it increased to -11.58 million. This year so far its at -12.75 million.

It’s not looking to good.